rheumatology
SLE Management
Diagnosis, hydroxychloroquine backbone therapy, and organ-specific management of SLE
Source: EULAR 2023 / BSR
Step 1 of ~8
info
SLE Diagnosis
2019 EULAR/ACR criteria. Entry criterion: ANA ≥1:80. Additional domains: constitutional, haematological, neuropsychiatric, mucocutaneous, serosal, musculoskeletal, renal, anti-dsDNA/Sm, complement (C3/C4).
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Asfotase Alfa · Enzyme Replacement Therapy (Hypophosphatasia — Tissue Non-specific Alkaline Phosphatase)
- Insulin (IV Infusion — ICU Glucose Control) · Insulin — ICU Glucose Management
- Sodium Chloride 3% (Hypertonic Saline) · Hypertonic Electrolyte Solution — ICP/Hyponatraemia Management
- Digoxin-specific Antibody Fragments (DigiFab) · Antidote
- Hydroxychloroquine · Antimalarial — Lupus / Dermatoses
- Idarucizumab (Praxbind) · Dabigatran reversal agent (specific antidote)
Decision support only. Always apply local guidelines and clinical judgement.